Botulinum Toxin A as Treatment for Chronic Postsurgical Pain Following Lung Cancer Surgery

NCT ID: NCT04585620

Last Updated: 2021-11-09

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-09-01
• Study Completion Date: 2024-01-31

Brief Summary

Chronic postsurgical pain following lung cancer surgery is common with and 20-60 % develop chronic pain which persists more than six months after surgery. Causes and health impact of this pain have been comprehensively studied. Current treatment consists of combination of pain medication, physiotherapy and psychological therapy.

Botulinum Toxin A (BTX-A) has shown promising effects in a variety of chronic postsurgical pain syndromes. The use of BTX-A in lung cancer patients has only been presented in few case reports. No randomized controlled trials (RCT) have been executed to date.

Study objectives:

Determine recruitment potential among cured lung cancer patients with chronic postsurgical pain for an RCT and if the method of BTX-A administration is feasible and acceptable. Further more, this study will contribute to the stage testing of the hypothesis that chronic pain following thoracic surgery can be treated with BTX-A.

Methods:

Recruitment of test subjects:

Participiants are recruited among former lung cancer patients with chronic postsurgical pain, who have undergone radical treatment for lung cancer at the Department of Cardiothoracic Surgery, Aalborg University Hospital. Potential test subjects are invited by mail / e-mail.

Randomization and blinding:

Participants are randomized to receive a single series of subcutaneous injections with either Onabotulinum Toxin A (active agent) or inactive normal saline (Placebo) at the former operation site. Neither participant nor investigator will know which treatment is given until the end of the trial.

Data collection:

Data is collected by questionnaires delivered and answered by mail or digitally.

Data on the possible effects and possible adverse reactions are collected at multiple times until three months after treatment.

Detailed Description

Chronic postsurgical pain (CPP) following lung cancer surgery is common with an observed prevalence of 20-60 %. Causes and health impact have been comprehensively studied. Current treatment consists of combination of pain medication, physiotherapy and psychological therapy.

Botulinum Toxin A (BTX-A) has shown promising effects in a variety of chronic postsurgical pain syndromes. The use of BTX-A in lung cancer patients has only been presented in few case reports. No randomized clinical controlled trials (RCT) has been executed to date.

Study objectives:

Primary:

Determine recruitment potential among cured lung cancer patients with CPP for an RCT and if the method of BTX-A administration is feasible and acceptable to the test subjects.

Secondary:

Early stage testing of the hypothesis that CPP following thoracic surgery can be treated with this novel method.

Methods:

Recruitment of test subjects:

Test subjects are recruited among former lung cancer patients with chronic postsurgical pain, who have undergone radical treatment for lung cancer at the Department of Cardiothoracic Surgery, Aalborg University Hospital. Potential test subjects are invited by mail / e-mail.

Randomization and blinding:

Test subjects are randomized to receive a series of injections with either Onabotulinum Toxin A (active agent) or inactive normal saline (Placebo). Neither test subject nor investigator will know which treatment is given until the end of the trial.

Experimental treatment:

The investigator examines the skin area of the test subject at the operation site and performs a sensory examination with pin prick and sensory brush. The area is located and marked and divided into quadrants of one square centimeter. An area of maximum 40 square centimeters is marked.

At a single treatment session, test subjects receives either active agent or placebo through a series of subcutaneous injections. One injection is given in each marked quadrant of the treatment area. The maximal number of injections is 40.

Follow-up:

After the treatment, test subjects report pain symptoms and intensity, use of pain medication and occurrence of adverse events weekly.

After 30 and 90 days after treatment more comprehensive and additional data is collected concerning neuropathic symptoms, activities of daily life, general health and level of function.

Data collection Data is collected by questionnaires delivered to test subjects by mail or digitally.

Endpoints:

Primary:

1. Recruitment of 30 test subjects.

2. Half of the first half of included test subject must complete the treatment.

3. Half of test subjects in total mus complete the treatment.

Secondary:

1. Pain at rest, coughing and when active Numerical rating score (NRS) for presence of pain before and after treatment and course of pain symptoms.

2. General Health Short form 36 Health Survey on physical, social and mental level of function on a score from 0 to 100.

3. Neuropathic Pain Symptoms Inventory (NPSI) NRS

4. Activities of daily life Impact and intensity of pain categorically in 16 situations of daily life.

5. Patient's Global Impression of Change (PGIC) Rating of global change perceived by the test subject from "More Worse" to "Much better" and a scale from 0 to 10.

Conditions

Chronic Pain; Post-thoracotomy Pain Syndrome; Pain, Neuropathic; Pain, Postoperative

Keywords

Botulinum toxin; Onabotulinum toxin A

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

BTX-A

Onabotulinum toxin A is reconstructed with 4 ml of normal saline in a vial containing 100 U (Allergen Units).

At a single treatment session, test subjects receive a series of subcutaneous injections with 2,5 U Onabotulinum toxin A equivalent to 0,1 ml of solution after reconstruction. One injection is given per 1 square centimeter in the painful area in relation to the scar on the chest wall. The maximum number of subcutaneous injections is 40, equivalent to a maximum dose of 100 U of Onabotulinum toxin in a total volume of 4 ml solution. The subcutaneous injections are administered using 26G 0.45 x 15 mm cannulae and 1 ml syringes.

Group Type: ACTIVE_COMPARATOR

Onabotulinum Toxin A

Intervention Type: DRUG

Series of subcutaneous injections

Placebo

At a single treatment session, test subjects receive a series of subcutaneous injections with one injection per 1 square centimeter in the painful area in relation to the scar on the chest wall with an inert solution, i.e. 0.1 ml injections of normal saline up to a total volume of 4 ml, depending on the area of the painful area. The subcutaneous injections are administered using 26G 0.45 x 15 mm cannulae and 1 ml syringes.

Group Type: PLACEBO_COMPARATOR

Normal saline

Intervention Type: DRUG

Series of subcutaneous injections

Interventions

Onabotulinum Toxin A

Series of subcutaneous injections

Intervention Type: DRUG

Normal saline

Series of subcutaneous injections

Intervention Type: DRUG

Other Intervention Names

BTX-A; Placebo

Eligibility Criteria

Inclusion Criteria

1. Patients of 18 years of age or above.

2. Patients who have undergone pulmonary surgery because of suspicion or confirmed pulmonary malignancies.

3. Patients who are radically treated for pulmonary malignancy

4. Patients who suffers from chronic pain or unpleasant sensation at the site of scar at least six months after surgery with fully healed surgical wounds.

Exclusion Criteria

1. Patients who cannot understand oral and written information.

2. Patients who were not radically operated.

3. Patients with other concomitant or other active cancer diseases.

4. Patients with chronic pain in the chest wall prior to surgery.

5. Pregnant women or women planning to get pregnant in the study period.

6. Patients with autoimmune neuromuscular diseases, sclerosis, peripheral neuromuscular disturbances and general muscle weakness or atrophy.

7. Patients with intolerance or allergy to BOTOX®.

8. Patients who are at present treated with BTX-A or similar neuromuscular blocking drug or have received such in the past year.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Allan Vestergaard Danielsen, MD

OTHER

Sponsor Role: lead

Responsible Party

Allan Vestergaard Danielsen, MD

Principal Investigator

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Allan V Danielsen, MD

Role: PRINCIPAL_INVESTIGATOR

Dept. of Cardiothoracic Surgery, Aalborg University Hospital

Locations

Dept. of Cardiothoracic Surgery, Aalborg University Hospital

Aalborg, , Denmark

Countries

Denmark

Central Contacts

Allan V Danielsen, MD

Role: CONTACT

Phone: +45 29720229

Email: a.danielsen@rn.dk

Jan J Andreasen, MD PhD

Role: CONTACT

Phone: +45 9766 4651

Email: jja@rn.dk

Facility Contacts

Allan V Danielsen, MD

Role: primary

Jan J Andreasen, MD PhD

Role: backup

Other Identifiers

74719

Identifier Type: -

Identifier Source: org_study_id